The NeoPhore team attended the American Association for Cancer Research Annual Meeting in San Diego, 5 - 10 April 2024.
In collaboration with The University of Turin, NeoPhore presented preclinical data from our PMS2 program.
The poster presentation 'Pharmacological inhibition of PMS2 increases tumor mutational burden, induces microsatellite instability and elicits immune mediated rejection in vivo' took place on Tuesday 9th April during Session PO.ET06.05 - Novel Therapeutics and Preclinical Models .
To download the poster (only available from 15th April 2024) please submit the form below or request a copy via this email address.